Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference
09 November 2022 - 11:00PM
Business Wire
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced
that it will participate in a fireside chat at the Jefferies London
Healthcare Conference on November 16, 2022, at 10:20 a.m. GMT.
A webcast of the presentation may be accessed in the Investors
section of the Company’s website at www.concertpharma.com. A replay
will be available on Concert’s website for two weeks following the
presentation.
About Concert
Concert Pharmaceuticals is a late-stage clinical
biopharmaceutical company that is developing deuruxolitinib
(CTP-543), a novel, deuterated, oral JAK1/2 inhibitor. Concert has
successfully completed two Phase 3 trials with deuruxolitinib in
adults with alopecia areata, a serious autoimmune dermatological
disease. The Company is also evaluating the use of deuruxolitinib
in other indications and assessing a number of earlier-stage
pipeline candidates. For more information, please visit
www.concertpharma.com or follow us on Twitter, Instagram or
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221109005071/en/
Justine Koenigsberg (781) 674-5284 ir@concertpharma.com
Concert Pharmaceuticals (NASDAQ:CNCE)
Historical Stock Chart
From Jul 2024 to Jul 2024
Concert Pharmaceuticals (NASDAQ:CNCE)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Concert Pharmaceuticals Inc (NASDAQ): 0 recent articles
More Concert Pharmaceuticals Inc News Articles